The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Reversal of Dopamine Supersensitivity as a Mechanism of Action of Clozapine
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Similar mechanisms, subsumed under the concept of supersensitivity psychosis, may apply to the use of antipsychotics in schizophrenia and mood disorders.
“Similar mechanisms, subsumed under the concept of supersensitivity psychosis, may apply to the use of antipsychotics in schizophrenia and mood disorders.78,79”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [79]
Citations
Cites
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270
All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors
Seeman, P. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00162.x · Cited by 228
Potvin, S., Stip, E., & Roy, J. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000063501.97247.38 · Cited by 69
Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice
Nakata, Y., Kanahara, N., & Iyo, M. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117728428 · Cited by 52
Davidson, C., Lazarus, C., Xiong, X., Lee, T. H., & Ellinwood, E. H. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02390-7 · Cited by 41
Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia
Nakata, Y., Kanahara, N., Kimura, H., Watanabe, H., & Iyo, M. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000160 · Cited by 23
Effects of clozapine on behavioral sensitization induced by cocaine
Park, H.-J., Cui, F. J., Hwang, J. Y., & Kang, U. G. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2008.10.005 · Cited by 17
Treatment of the Psychostimulant-Sensitized Animal Model of Schizophrenia
Shuto, T., & Nishi, A. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00218.x · Cited by 16
Kawano, M., Oshibuchi, H., Kawano, T., Muraoka, H., Tsutsumi, T., Yamada, M., Inada, K., & Ishigooka, J. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.04.013 · Cited by 15
Cha, S. K., & Kang, U. G. (2014) · Psychiatry Investigation · doi:10.4306/pi.2014.11.4.454 · Cited by 5
Flagged first, then by citations
Cited by
Sorted by citations
de Bartolomeis, A., Vellucci, L., Barone, A., Manchia, M., Luca, V. D., Iasevoli, F., & Correll, C. U. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108236 · Cited by 93
Fava, G. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320970325 · Cited by 84
A Focused Review of the Metabolic Side-Effects of Clozapine
Yuen, J. W. Y., Kim, D. D., Procyshyn, R. M., Panenka, W. J., Honer, W. G., & Barr, A. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.609240 · Cited by 98
Self-citationGammon, D., Cheng, C. M. C., Volkovinskaia, A., Baker, G. B., & Dursun, S. M. (2021) · Biomolecules · doi:10.3390/biom11071030 · Cited by 79
Kim, D. D., Barr, A. M., Lian, L., Yuen, J. W. Y., Fredrikson, D. H., Honer, W. G., Thornton, A. E., & Procyshyn, R. M. (2021) · Schizophrenia · doi:10.1038/s41537-021-00158-z · Cited by 23
Self-citationAntipsychotic polypharmacy in schizophrenia: evolving evidence and rationale
Azorin, J., & Simon, N. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1821646 · Cited by 22
Regen, F., Cosma, N. C., Otto, L. R., Clemens, V., Saksone, L., Gellrich, J., Üsekes, B., Ta, T. M. T., Hahn, E. W., Dettling, M., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0791-8 · Cited by 25
Kimura, H., Kanahara, N., & Iyo, M. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113126 · Cited by 16
Decoding Clozapine-Induced Agranulocytosis: Unraveling Interactions and Mitigation Strategies
Alalawi, A. M., Albalawi, E., Aljohani, A., Almutairi, A., Alrehili, A., Albalawi, A., & Aldhafiri, A. J. (2024) · Pharmacy · doi:10.3390/pharmacy12030092 · Cited by 10
Kobayashi, R., Oda, Y., Hayatsu, R., Ohki, N., Akutsu, M., Oiwa, T., Komatsu, H., Niitsu, T., Sasaki, T. G., & Iyo, M. (2020) · SAGE Open Medical Case Reports · doi:10.1177/2050313x20929561 · Cited by 4
Relationship between clozapine dose and severity of obsessive-compulsive symptoms
Kim, D. D., Barr, A. M., Stewart, S. E., White, R. F., Honer, W. G., & Procyshyn, R. M. (2021) · Medical Hypotheses · doi:10.1016/j.mehy.2021.110506 · Cited by 4
Self-citationde Bartolomeis, A., Vellucci, L., Barone, A., Manchia, M., Luca, V. D., Iasevoli, F., & Correll, C. U. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4089530 · Cited by 4
Randomised controlled trial of clozapine in resistant schizophrenia and schizoaffective disorder
Peraire, M., Arnau, F., Villar-García, M., Benito, A., Echeverria, I., & Haro, G. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251355602 · Cited by 3
Parikh, P., Wubuli, D., Dadem, A. R., Gultekin, I., Chandra-Kaushik, A., Wang, E., Narravula, R., Chandra, A., Buddhavarapu, I., & Mendelowitz, A. (2025) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20253283
Metadata
- Authors
- Kim, D. D., Barr, A. M., Honer, W. G., & Procyshyn, R. M.
- Affiliations
- University of British Columbia (CA)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2018
- Volume
- 87
- Issue
- 5
- Pages
- 306-307
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2883082031
- Cited by
- 14
- References
- 10
- Citations by year
- 2025: 2 · 2024: 1 · 2022: 2 · 2021: 5 · 2020: 4
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- clozapine, dopamine supersensitivity, dopamine receptor antagonism, mechanism of action, antipsychotic drugs
- MeSH terms
- Animals, Clozapine, Humans, Psychotic Disorders, Schizophrenia, Antipsychotic Agents, Dopamine Agents, Central Nervous System Sensitization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
